Hyperhomocysteinemia as a Risk Factor for Intracranial Aneurysms: A Case-Control Study
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Citação
WORLD NEUROSURGERY, v.119, p.E272-E275, 2018
Resumo
OBJECTIVE: Homocysteine, an amino acid derived from methionine metabolism, has gained great importance as an important risk factor for cardiovascular diseases as the result of its thrombogenic properties and endothelial injury association. However, its role in the etiology and screening of intracranial aneurysms (IAs) has not been well studied. We aimed to test the hypothesis of a positive association between hyperhomocysteinemia (HHcy) and IAs. METHODS: A case-control study was performed at a vascular neurosurgery unit in Brazil between 2016 and 2017. In total, 180 patients were included: 142 patients with previous IAs (case group) and 38 patients with a previous diagnosis of arteriovenous malformation and no aneurysms on imaging evaluation (control group). HHcy was defined as homocysteine levels greater than 15 mu mol/L. Multivariate models were designed to adjust for potential confounders: age, sex, hypertension, dyslipidemia, and smoker status. RESULTS: The case group was older (56.3 + 12.6 years vs. 40.9 +/- 14.0 years, P < 0.001) and had a greater prevalence of women (76.1% vs. 55.3%, P = 0.012), as well as hypertension (45.1% vs. 2.6%, P < 0.001), dyslipidemia (60.6% vs. 10.5%, P = 0.001), and smokers (41.5% vs. 0.0%, P < 0.001). Median homocysteine in the cases was similar to the controls (10.5 mu mol/L [8.3-14.0] vs. 10.7 mu mol/L [8.2-13.3], respectively, P = 0.450). There was a trend toward greater HHcy prevalence in the case group (20.4% vs. 7.9%, P = 0.073). HHcy was associated with greater age, male sex, hypertension, and smoking status. After multivariate adjustment, HHcy had no association with IAs (odds ratio 1.34, 95% confidence interval 0.30-5.97, P = 0.703). CONCLUSIONS: No association was found between HHcy and IAs.
Palavras-chave
Cerebrovascular disease, Homocysteine, Hyperhomocysteinemia, Intracranial aneurysm, Risk factor
Referências
- Cao H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085831
- Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)17742-3
- CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
- Duncan IC, 2005, AM J NEURORADIOL, V26, P2030
- Fu Y, 2018, BRIT J PHARMACOL, V175, P1173, DOI 10.1111/bph.13988
- Ganguly P, 2015, NUTR J, V14, DOI 10.1186/1475-2891-14-6
- Hickey SE, 2013, GENET MED, V15, P153, DOI 10.1038/gim.2012.165
- Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024
- Korai M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0634-3
- Li TY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02401-7
- Linnebank M, 2006, STROKE, V37, P2840, DOI 10.1161/01.STR.0000244764.02851.d3
- Moroz P, 2007, ANZ J SURG, V77, P329, DOI 10.1111/j.1445-2197.2007.04052.x
- Ren JR, 2017, J STROKE CEREBROVASC, V26, P2720, DOI 10.1016/j.jstrokecerebrovasdis.2017.01.001
- Semmler A, 2008, CEREBROVASC DIS, V26, P425, DOI 10.1159/000155638
- Truelsen T., 2000, GLOBAL BURDEN CEREBR
- Xu Y, 2011, NEUROSCI LETT, V494, P139, DOI 10.1016/j.neulet.2011.02.076